Effects of ondansetron on respiratory pattern and sensation of experimentally induced dyspnea
Keywords:
Dyspnea, Ondansetron, Pulmonary Function, Analog ScaleAbstract
CONTEXT: Dyspnea remains a therapeutic challenge, especially in chronic respiratory conditions. Recent studies have shown that the induction of unpleasant dyspnea sensations activates areas in the insular cortex. OBJECTIVE: This study was designed to investigate the potential effects of ondansetron, a potent antiserotonin agent, on induced dyspnea sensation. TYPE OF STUDY: A randomized double blind study. SETTING: Pulmonary Function Laboratory of Hospital das Clínicas de Ribeirão Preto. PARTICIPANTS: Ten healthy male volunteers (mean age ± standard error = 23.1 ± 0.41 years) without respiratory diseases and showing normal spirometric tests. INTERVENTIONS: Uncomfortable breathing was induced in the volunteers on two different days, via the use of inspiratory resistors (loads of 0, 7, 14 and 21 cm H2O/l/sec) and breathholding, two hours after taking 8 mg of ondansetron (Ond) or placebo (Plac). MAIN MEASUREMENTS: Respiratory discomfort during breathing under loading was evaluated on a 100-mm visual analog scale. The maximum length of time of voluntary apnea was measured in seconds. RESULTS: The mean maximum voluntary apnea time did not differ between the ondansetron and placebo days (Plac = 96 ± 6.6 sec vs. Ond = 100 ± 7.9 sec). Ondansetron did not influence the dyspnea sensation induced by different inspiratory loads (0 cm H2O/l/sec: Ond = 1.4 mm ± 0.44 vs. Plac = 2.1 ± 0.85 mm; 7 cm H2O/l/ sec: Ond = 16.6 ± 2.74 mm vs. Plac = 13.7 ± 2.06 mm; 14 cm H2O/l/sec; Ond = 30.5 ± 4.50 mm vs. Plac = 27.1 ± 3.44 mm; 21 cm H2O/l/ sec: Ond = 50.3 ± 6.72 mm vs. Plac = 49.4 ± 6.72 mm). Ondansetron led to significant decreases in tidal volume under basal conditions and when breathing under the highest inspiratory loading (0 cm H2O/l/sec: Ond = 0.83 ± 0.26 l vs. Plac = 1.0 ± 0.28 l; 21 cm H2O/l/sec: Ond = 0.86 ± 0.23 l vs. Plac = 1.1 ± 0.22 l) CONCLUSION: The present results suggest that 5-HT3 receptors do not play an important role in the mediation of dyspnea sensations.
Downloads
References
American Thoracic Society. Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999;159:321-40.
Martinez JAB, Pádua A. Dispnéia: novos conhecimentos sobre um velho problema. In: Terra Filho, M, Fernandes, ALG. Stirbulov R, editors. Pneumologia: Atualização e Reciclagem. Volume IV. São Paulo: Vivali 2001.
Mahler DA, Mackowiak JI. Evaluation of the short-form 36- item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995;107:1585-9.
Martinez TY, Pereira CAC, dos Santos ML, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000;117:1627-32.
Stark RD, Russell NJW, Stark AC. Dyspnea: a possible target for pharmacological intervention. In: Adams L, Guz A, editors. Lung biology in health and disease. Respiratory sensation. New York: Marcel Decker; 1996.p.341-63.
Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995;333:1547-52.
Bonham AC. Neurotransmitters in the CNS control of breath- ing. Respir Physiol 1995;101:219-30.
Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25(Suppl 1):21-4.
Bryson JL. Clinical safety of ondansetron. Semin Oncol 1992;19(Suppl 12):S26-S32.
Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. JAMA 2000;282:963-71.
Roychoudhury M, Kulkarni SK. Effects of ondansetron on short-term memory retrieval in mice. Methods Find Exp Clin Pharmacol 1997;19:43-6.
Roychoudhury M, Kulkarni SK. Antianxiety profile of ondansetron, a selective 5-HT3 antagonist in a novel animal model. Methods Find Exp Clin Pharmacol 1997;19:107-11.
Faris PL, Kim SW, Meller WH, et al. Effect of ondansetron on symptoms of bulimia nervosa: a randomized, double blind trial. Lancet 2000;355:792-7.
Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 2000;113(Suppl)S37-S45.
Hasler WL. Serotonin receptor physiology: relation to emesis. Dig Dis Sci 1999;44(Suppl):S108-S113.
American Thoracic Society. Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-98.
Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recom- mendations. Am Rev Respir Dis 1981;123:659-64.
Aitken RCB. Measurement of feelings using visual analogue scales. Proc R Soc Med 1969;62:989-93.
Banzett RB, Mulnier HE, Murphy K, et al. Breathlessness in humans activates insular cortex. Neuroreport 2000;11:2117-20.
Peiffer C, Poline JB, Thivard L, Aubier M, Sanson Y. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med 2001;163:951-7.
Kinomura S, Kawashima R, Yamada K, et al. Functional anatomy of taste perception in the human brain studied with positron emission tomography. Brain Res 1994;659:263-6.
Casey KL. Forebrain mechanisms of nociception and pain: analy- sis through imaging. Proc Natl Acad Sci USA 1999;96:7668- 74.
Miller AD, Rowley HA, Roberts TPL, Kucharczyk J. Human cortical activity during vestibular and drug induced nausea de- tected using MSI. Ann NY Acad Sci 1996;781:670-2.
Cechetto DF. Central representation of visceral function. Fed Proc 1987;46:17-23.
O’Neill PA, Stark RD, Morton PB. Do prostaglandins have a role in breathlessness? Am Rev Respir Dis 1985;132:22-4.
Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000;161:1963-7.
Rang HP, Dale MM, Ritter JM. Other peripheral mediators: 5- hydroxytryptamine and purines. In: Rang HP, Dale MM, Ritter JM, editors. Pharmacology. Edinburgh: Churchill Livingstone, 1995.p.177-90.
Armstrong DJ, Kay IS. 5-hydroxytryptamine mediates the post- embolic increase in respiratory rate in anaesthetized rabbits. Exp Physiol 1990;475-81.
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-152.
Mitchell EA, Pratt JA. Neuroanatomical structures involved in the action of the 5-HT3 antagonist ondansetron: a 2- deoxyglucose autoradiographic study in the rat. Brain Res 1991;538:289-94.
Freo U. Cerebral metabolic effects of serotonin drugs and neurotoxins. Life Sci 1996;59:877-91.
Martinez JAB, Straccia L, Sobrani E, et al. Dyspnea scales in the assessment of illiterate patients with chronic obstructive pulmonary disease. Am J Med Sci 2000;320:240-3.
